Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
9,43 USD | -5,70 % | -.--% | -5,70 % |
Resumen de negocios
Número de empleados: 350
Ventas por actividad
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 15 569 | 100,0 % | 12 766 | 100,0 % | -18,00 % |
Ventas por región
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Japan
48,4
%
| 80 | 0,5 % | 6 173 | 48,4 % | +7.616,25 % |
Switzerland
31,4
%
| 2 564 | 16,5 % | 4 004 | 31,4 % | +56,16 % |
United States
10,8
%
| 9 934 | 63,8 % | 1 373 | 10,8 % | -86,18 % |
Bermuda
9,5
%
| 2 849 | 18,3 % | 1 212 | 9,5 % | -57,46 % |
United Kingdom
0,0
%
| 142 | 0,9 % | 4 | 0,0 % | -97,18 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/09/17 |
Shinichi Tamura
FOU | Founder | 74 | 22/06/90 |
Director of Finance/CFO | - | 24/03/22 | |
Compliance Officer | 70 | 01/04/15 | |
Satoshi Tanaka
PRN | Corporate Officer/Principal | - | 01/07/23 |
Kieran Johnson
AUD | Comptroller/Controller/Auditor | 55 | 24/03/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 22/06/90 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 27/03/19 |
Rolf Soderstrom
BRD | Director/Board Member | 59 | 25/03/20 |
Kuniaki Kaga
BRD | Director/Board Member | 72 | 22/06/18 |
Tomohiro Toyama
BRD | Director/Board Member | 74 | 01/06/11 |
David Roblin
BRD | Director/Board Member | 57 | 22/06/18 |
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/09/17 |
Miwa Seki
BRD | Director/Board Member | 59 | 24/03/22 |
Eiko Tomita
BRD | Director/Board Member | - | - |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 89 446 777 | 81 288 920 ( 90,88 %) | 1 121 ( 0,001253 %) | 90,88 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
BIOHAVEN LTD. 0.03% | 27 308 | 0.03% | 958 511 $ |
NXERA PHARMA CO., LTD. 0.00% | 300 | 0.00% | 2 772 $ |
Información de la empresa
Sosei Group Corp.
PMO Hanzomon, 11/F 2-1 Koji-machi
102-0083, Tokyo
+81 3 5210 3290
https://soseiheptares.comEmpresas del grupo
Nombre | Categoría y sector |
---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. |
Pharmaceuticals: Major
|
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+6,58 % | 39,05 mil M | |
-11,57 % | 33,74 mil M | |
+79,15 % | 28,54 mil M | |
-14,73 % | 15,59 mil M | |
-6,00 % | 13,69 mil M | |
-12,55 % | 11,44 mil M | |
+166,50 % | 10,66 mil M | |
-54,80 % | 9274,4 M | |
+4,19 % | 9130,96 M |
- Bolsa de valores
- Acciones
- Acción 4565
- Acción SOLT.F
- Empresa Nxera Pharma Co., Ltd.